Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: placebopatients mustheartdiseasewomen of
  Phrases that lowered it: mmhgblood pressureessential hypertensionsittingto evaluate
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.5% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 9.8% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 77.8% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 264 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 237 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 22851 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Blinding: double (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 5754 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension NCT01785472 · started 2013 · scored riskier than 30% of active trials completed
• Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension NCT01599104 · started 2012 · scored riskier than 28% of active trials completed
• Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan NCT01876368 · started 2013 · scored riskier than 24% of active trials completed
• A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension NCT00817635 · started 2008 · scored riskier than 18% of active trials completed
• Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy NCT06236061 · started 2024 · scored riskier than 30% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.